Post-streptokinase PCI in STEMI patients exceeding the 24-h guidelines

El-Zahraa M. Esmat Sultan*, Khaled R. Abdel Meguid and Hesham B. Mahmoud

Abstract

Background: Due to delay in obtaining approval from insurance institution, performing PCI after successful reperfusion using streptokinase was postponed for >24 h–1 week. The study was conducted to investigate safety and efficacy of such delay in comparison to the ideal guidelines of PCI (≤24 h) in 129 STEMI patients received streptokinase followed by PCI. Patients were divided into two groups: (group 1 = 57; early PCI ≤24 h) and (group 2 = 72; late PCI > 24 h).

Results: Primary end point was death, congestive heart failure and reinfarction up to 30 days. Secondary end point was TIMI flow < G3, ischemic stroke, intracranial hemorrhage and non-intracranial bleeding. No statistical significant difference was found between both groups regarding LVEF, dimensions and myocardium wall preservation and incidence of complications and TIMI flow. No primary endpoints were detected. Five patients had secondary endpoints in early PCI and four in the late PCI. Suction device and IV Eptifibatide were used more in early PCI (p = 0.003).

Conclusions: The study suggests that relatively late PCI (> 24 h–1wk) after successful reperfusion using streptokinase in STEMI patients seems to be safe and effective in 30-day follow-up, provided that patients received DAPT and were subjected to close observation. The results seem safely applicable when we are forced to this choice; however lack of more investigations to this hypothesis is considered a limitation.

Keywords: Pharmaco-invasive (PI), ST-segment elevation myocardial infarction (STEMI), Streptokinase (SK), Coronary Angiography (CA), Percutaneous coronary intervention (PCI)

1 Background

While primary percutaneous coronary intervention (PPCI) is the first choice in managing patients with ST-segment elevation (STEMI)[1], Pharmaco-invasive approach is frequently used in many developing countries[2, 3]. When PPCI is not available, pharmaco-invasive approach is often a more suitable choice. Guidelines for managing STEMI patients illustrated ideal clinical practice of reperfusion by fibrinolytic followed by PCI within 24 h[4] [1]. Due to delay in obtaining approval from the insurance institution, performing PCI was postponed for more than 24 h and up to one week; however, most of the patients were kept in the hospital till receiving the financial approval. Therefore, this study was conducted to investigate the safety and the efficacy of such delay in performing PCI (>24 h) in comparison to the ideal prescribed guidelines of earlier PCI (≤24 h) following successful reperfusion using streptokinase.

2 Methods

2.1 Study design

This is an observational cross-sectional study. It included 129 STEMI patients between October 2014 and August 2018. All the patients were presented with chest pain up to twelve hours from the onset of symptoms and were given one and a half million units of Streptokinase (SK). Successfully reperfused patients (129 patients) were divided into two groups according to the time between successful reperfusion and PCI performance: Group 1 = 57 patients had early PCI 3–24 h, whereas
Group 2 = 72 patients had a delayed PCI > 24 h after Streptokinase.

2.2 Reperfusion by SK and its assessment
SK was administered (1.5 million units over 30–60 min.) and was combined with IV enoxaparin (30-mg) followed by subcutaneous injection of 1 mg /Kg of body weight. A loading dose of clopidogrel 300-mg was administrated followed by 150 mg for the first 2 weeks then 75 mg daily. In addition, a loading dose of aspirin was given: 300 mg; this was followed by 81 mg daily. Successful reperfusion was confirmed in all patients by resolutions of ST elevation > 50–70% at 60 to 90 min after SK therapy; chest pain relief; or occurrence of reperfusion arrhythmias.

2.3 Primary and secondary end points
Patients were followed up for 30 days, looking for primary end point (death, congestive heart failure or reinfarction) and secondary end point (TIMI flow grade less than 3, ischemic stroke, intracranial hemorrhage or non-intracranial bleeding).

2.4 Statistical analyses
Data were analyzed using the software, Statistical Package for Social Science (SPSS Inc. Released 2009, PASW Statistics for Windows, version 18.0: SPSS Inc., Chicago, Illinois, USA). Frequency distribution as percentage and descriptive statistics in the form of mean and standard deviation were calculated. Chi-square, t test, one-way ANOVA and correlations were done whenever needed. P values of less than 0.05 were considered significant.

3 Results
3.1 Baseline patients’ characteristics
The mean age for all 129 pharmaco-invasive approach patients was (55.23 ± 10.62) year old with a minimum of 29 years and maximum 83 years (Table 1). There were 106 (82.2%) male patients and 23 (18.0%) female patients. Twenty-seven (20.9%) patients had a history of IHD and only 23 (17.8%) were on anti-ischemic drugs. Forty-two (33.6%) patients were diabetic, 52 (40.3%) were hypertensive and 76 (59.0%) were smokers. Successful reperfusion was confirmed by ST resolution, decrease/disappearance of chest pain or occurrence of reperfusion arrhythmia. Seventy patients had 50% ST resolution after 60–90 min, while 59 patients had 70% ST resolution. Reperfusion arrhythmias were detected in 28 (22%) patients only.

3.2 The procedure data
Radial access was used in 80 patients (62%) out of 129; 33 (41%) in group1 (≤ 24 h.) and 47 (59%) in (> 24 h.) group2. Suction devices were used in 6 patients (10.5%) in group 1 (≤ 24 h.), while it was used once (1.4%) in group 2 (> 24 h.); (p = 0.030). IV Eptifibatide administered in 7 patients (12.3%) in group 1 (≤ 24 h.), while it was not used in (> 24 h.) group 2; (p = 0.003) (Fig. 1).

3.3 TIMI final results
There was no statistical difference between both groups regarding reaching TIMI flow results; (p = 0.628) (Fig. 1). TIMI flow G3 was achieved in 54 (94.7%) patients in group 1 (≤ 24 h.) and 68 (94.4%) patients subsequently in group 2 (> 24 h.). TIMI flow G2 occurred in only 3 (5.3%) patients in group 1 (≤ 24 h.) and in 4 (5.6%) patients in group 2 (> 24 h.).

3.4 Echocardiographic data
No statistical significant difference was found between both groups regarding LVEF (p = 0.571), end-diastolic (p = 0.267) and end systolic dimensions (p = 0.948) (Fig. 2). In group 1 (≤ 24 h.), akinetic segments detected in 21 patients (36.8%) and 20 (27.8%) patients; (p = 0.108) in group 2 (> 24 h.).

Eighteen patients (31.6%) in group 1 showed hypokinetic segments versus 36 patients (50.0%) in group 2; (p = 0.105). Normal segment wall motion was detected in 18 patients (31.6%) in group 1 (≤ 24 h.) versus 16 patients (22.2%) in group 2 (> 24 h.); (p = 0.983).

Table 1 Baseline patients’ characteristics and ECG

| Variable | Pharmaco-invasive n = 129 (%) |
|----------|-----------------------------|
| Demographic |                                |
| Age (mean ± SD) years | (55.23 ± 10.62) |
| Sex |                                |
| Male | 106 (82.2) |
| Female | 23 (18.0) |
| CV history |                                |
| HTN | 52 (40.3) |
| DM | 42 (33.6) |
| History of IHD |                                |
| Adherence to anti-ischemic drugs^ | 23 (17.8) |
| Smoking | 76 (59.0) |
| ECG: successful reperfusion |                                |
| ST resolution after SK |                                |
| 50% | 70 (54.2) |
| 70% | 59 (45.7) |
| Reperfusion arrhythmia |                                |
| Yes | 28 (20.4) |

PPCI: Primary Percutaneous coronary Intervention; HD: Ischemic heart disease, HTN: Hypertension, DM: Diabetes; ^ Anti-ischemic medications: Aspirin, Clopidogrel, statins and Beta-Blockers, ± angiotensin-converting enzyme Inhibitors, ± Nitroglycerin

*p ≤ 0.05
Thinned walls were detected in 13 (22.8%) patients in the group1 (≤ 24 h.) against 12 (16.7%) patients in group 2 (> 24 h.).

3.5 Complications after 30 days follow-up
Primary end point (death, congestive heart failure or reinfarction) was not reported in both groups. Nine
patients had secondary end points all over the study. Three patients had TIMI flow G2 in group 1 (≤ 24 h.) versus 4 patients in group 2 (> 24 h.). One patient had ischemic stroke and another had non-major bleeding in the early group 1 (≤ 24 h.)

4 Discussion
Our study was an observational cross-sectional one, which investigates the safety and efficacy of performing PCI later than 24 h after successful fibrinolytic pharmaco-invasive approach reperfusion. The idea of the study was inspired by the unfortunate bureaucracy which delayed the financial approval on PCI from the insurance organization. Such delay was not consistent with all the guidelines [1, 5]; therefore, 80% of the patients were kept under observation in the hospital until PCI was done. The other patients (20%) were given strict instructions to rush to hospital on the occurrence of any chest pain and were daily followed up by phone. An assessment of such group of postponed PCI, contrary to the guidelines, was therefore worthwhile.

Most of the published trials had a window of 3–24 h after successful fibrinolysis [6–8]. In many trials, there was a wide variation of delay between successful thrombolysis to PCI. Median time of PCI in the CAPITAL-AMI trial [9] was 1.3 h, whereas in the GRACIA-1 trial it was 16.7 h [10]. A recent study by Salih Kilica, et al. [11] compared the outcomes of STEMI patients who received successful fibrinolytic treatment and performed PCI within 24—72 h (group 1) or > 72 h (group 2). Coronary angiography was performed within 2.17 ± 0.38 days in group-1 and 2.9 ± 11.5 days in the Group-2. MACE rate was higher in Group-2 (21.3%) than Group-1 (13.8%), but it was not statistically significant (p = 0.661), after 6 months follow-up. Long-term follow-up (median: 57 months) also revealed no statistical significant difference; 37.9% in Group-1 and 38.3% in Group-2 (p = 0.974). Their results showed no difference in MACE for both short- and long-term follow-up groups regarding overall cardiac mortality rate (7.9%), the re-infarction rate (19.7%) and heart failure (17.1%).

Suction device use and IV Eptifibatide administration rate were higher in the earlier PCI group (≤ 24 h). In this group, suction device was used in 6 patients and IV Eptifibatide was administrated in 7 patients, while only one patient used suction device in the delayed PCI group (> 24 h.) and no patients received IV Eptifibatide (Fig. 1). Radial access was used more commonly (62.0%) than femoral access (38.0%) of all 129 patients (Fig. 1); 33 (41%) group 1 (≤ 24 h.) and 47 (59%) in group 2 (> 24 h.). The Transradial approach (TRA) could lead to a decrease in incidence of overall bleeding complications [12, 13].

The unplanned delay in PCI timing after successful thrombolytic reperfusion (in second group > 24 h.) allows for more dual antiplatelet administration. This could diminish the SK-induced platelet aggregation effect [14]. Although no significant difference regarding complication results in both groups; (p = 0.189), earlier PCI had 2 patients one with an ischemic stroke and another one with non-major bleeding. This result illustrates that delay in PCI, after successful SK reperfusion, did not add extra ischemic complications, provided that patients were subject to some restrictions in activity and strict intake of DAPT and were closely observed.

5 Limitations
Larger sample size and longer follow-up time would provide more definitive results to this work. However, pharmaco-invasive approach was a temporary solution for the limited availability of PPCI. However, addressing the problem of bureaucracy leading to delay in obtaining the approval from the insurance institution is necessary to help patients from rural areas with non-PCI capable hospitals. Lack of more investigations to this hypothesis is considered a limitation.

6 Future direction
In our hospitals, more efforts should be directed toward decreasing the elapsing period science reperfusion with thrombolytic therapy till performing CA/PCI in patients with STEMI.

7 Conclusions
This study suggests that relatively late PCI (> 24 hours up to one week) after successful reperfusion using SK in STEMI patients seems to be safe and effective according to short-term follow-up, provided that patients received DAPT and were subjected to close observation. The results seem safely applicable when we are forced to this choice; however lack of more investigations to this hypothesis is considered a limitation.

Abbreviations
PPCI: Primary percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction; SK: Streptokinase; TIMI: The thrombolysis in myocardial infarction; IHD: Ischemic heart disease; LVEF: Left ventricular ejection fraction; TRA: Transradial approach.

Acknowledgements
We wish to acknowledge the help of Dr. Araf A., Department of Public Health, Faculty of Medicine Beni-Suef University, Graduate school of Medicine Osaka University, for providing the statistical analysis. Ahmed011172@med.bsu.edu.

Authors’ contributions
HBM was involved in methodology. ZME and HBM were involved in conceptualization. ZME was involved in investigation, data curation and writing—original draft preparation. KRA and HBM were involved in writing—review &
We declare that we do not have competing interests.

Competing interests

All participating patients and authors verbally agreed to publish this work considering the patient’s privacy rights.

Consent for publication

All participating patients in the study signed an informed consent and their privacy rights were observed.

Consent for publication

We declare that we do not have competing interests.

Received: 16 August 2021   Accepted: 12 October 2021

Published online: 30 October 2021

References

1. Ibanez B, James S, Agevall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 39(2):119–177

2. Zubaid M, Khrashah H, Alahmad B, Rashed W, Ridha M, Alenezi F et al (2020) Efficacy and safety of pharmacoinvasive strategy compared to primary percutaneous coronary intervention in the management of ST-segment elevation myocardial infarction: a prospective country-wide registry. Ann Glob Heal 86(1):1–10

3. Kumbhani DJ, Alexander T, Nallamothu BK, Menon V, Ayers C, Mullasseri AS. Pharmacoinvasive approach versus streptokinase in low to intermediate risk ST-segment elevation myocardial infarction patients: insights from the Tamil Nadu-STEMI Initiative. Am J Cardiovasc Drugs [Internet]. 2019;19(5):517–9. Available from: https://doi.org/10.1007/s40256-019-00327-7

4. Mentias A, Girotta S. Pharmacoinvasive Strategy: The answer to improving ST-elevation-myocardial infarction care. J Am Heart Assoc. 2020;9(12):e016831.

5. Anderson JL (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of cardiology foundation/american heart association task force on practice guidelines. Circulation 127(4):362–425

6. Bahmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S (2010) Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances. J Am Coll Cardiol 55(2):102–110

7. Cantor WJ, Ritchett D, Borgundvaag B, Ducas J, Hefflerman M, Cohen EA, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med [Internet]. 2009;360(26):2705–18. Available from: https://doi.org/10.1056/NEJMoa0908276

8. Di Marco C, Dudek D, Piscione F, Mielecki W, Savonitto S, Murenza E, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet [Internet]. 2008;371(9612):559–68. Available from: https://www.sciencedirect.com/science/article/pii/S0140673608602688

9. Le May MR, Wells GA, Labinaz M, Davies RF, Turek M, Leddy D, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol [Internet]. 2005;46(3):417–24. Available from: http://dx.doi.org/10.1016/j.jacc.2005.04.042

10. Fernandez-Avilés F, Alonso JJ, Castro-Beiras A, Vázquez N, Blanco J, Alonso-Briasles J, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACLA-1): a randomised controlled trial. Lancet [Internet]. 2004;364(9439):1045–53. Available from: https://www.sciencedirect.com/science/article/pii/S0140673604105911

11. Kilic S, Turkoglu C (2019) Timing of coronary angiography after successful fibrinolytic therapy in ST-segment elevated myocardial infarction. Cardiol Res 10(1):34–39

12. Sultan E-ZM, Rabea HM, abdelmeguid KR, Mahmoud HB. Transradial artery approach in STEMI patients reperfused early and late by either primary PCI or pharmacoinvasive approach. Egypt Heart J [Internet]. 2018;70(1):1–7. Available from: https://www.sciencedirect.com/science/article/pii/S1110260816301624

13. Bernat I, Horak D, Stasek J, Mates M, Pesek J, Ostdal P et al (2014) ST-segment elevation myocardial infarction treated by radial or femoral approach in a multicenter randomized clinical trial: the STEMI-RADIAL trial. J Am Coll Cardiol 63(10):964–972

14. Vaughan DE, Van Houtte E, Declerck PJ, Colleen D (1991) Streptokinase-induced platelet aggregation: prevalence and mechanism. Circulation 84(1):84–91

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.